Exercise-responsive endocrine-metabolic mediators in diabetes and cardiometabolic disorders: a systematic scoping review and evidence map.

Front Endocrinol (Lausanne)Sep 22, 2026 (epub)
Clinical ResearchEndocrinologyCardiologyOpen access

Zihang Zhao, Yousheng Zhang, Zihan Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic scoping review examined exercise-responsive endocrine-metabolic mediators in diabetes and cardiometabolic disorders, analyzing 365 reports from 363 studies. The review found that 90.9% of studies identified exercise-responsive evidence, while 87.0% showed cardiometabolic associations. Adipokines, particularly adiponectin and leptin, were the most frequently represented mediators.

Key findings

  • 90.9% of studies identified exercise-responsive evidence related to mediators.
  • 87.0% of studies showed cardiometabolic associations with exercise.
  • Adipokines were present in 58.4% of studies contributing named mediators.
  • Chronic training accounted for 81.6% of exercise contrasts analyzed.

Why it matters

Understanding the role of exercise-responsive mediators can inform strategies for managing diabetes and cardiometabolic disorders. This knowledge may enhance the effectiveness of physical activity interventions in clinical practice.

Source

PubMed · PMID 42787687Free full text on PubMed Central

Published in Front Endocrinol (Lausanne). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.